BTIG Starts Jasper Therapeutics (JSPR) at Buy

BTIG analyst Justin Zelin initiates coverage on Jasper Therapeutics (NASDAQ: JSPR) with a Buy rating and a price target of $90.00.

The analyst said: "We see Jasper's briquilimab offering an attractive pipeline in a product with compelling market potential in addressing chronic urticaria, a large lucrative market not well-served by available therapies, in severe asthma, and in expansion indications. Depleting mast cells through c-KIT inhibition has been de-risked by impressive clinical data from Celldex's (CLDX, Not Rated) barzolvolimab, and we think briquilimab could be positively differentiated on safety, efficacy, and a more convenient and less frequent dosing regimen, offering competitive commercial advantages. We think Jasper has a strong catalyst path ahead where we expect initial Ph I/II BEACON CSU data in 3Q24 will be a positive catalyst for JSPR shares to narrow the $2B valuation gap with CLDX."

For an analyst ratings summary and ratings history on Jasper Therapeutics click here. For more ratings news on Jasper Therapeutics click here.

Shares of Jasper Therapeutics closed at $21.14 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy